We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
NPS sells Regpara royalties to DRI Capital for $38.4mm
13 Sep 2018
Executive Summary
NPS Pharmaceuticals (therapeutics for gastrointestinal and endocrine disorders) has sold some of its royalty rights pertaining to the hyperparathyroidism drug Regpara (cinacalcet; sold as Sensipar in the US and Mimpara in Europe) to a fund managed by DRI Capital for $38.4mm. NPS retains royalties in excess of $96mm or 2.5 times the up-front purchase price. DRI will receive royalty payments from sales occurring on or after July 1, 2009. NPS plans to use the money for Phase III registration studies of its two lead candidates--Gattex (teduglutide) for short bowel syndrome and NPSP558 for hypoparathyroidism. Since 1995, Kyowa Hakko Kirin has had rights to develop and commercialize Regpara in China, Japan, North Korea, South Korea, and Taiwan; the company launched the drug in Japan in 2008. In 1996, NPS licensed Amgen rights to cinacalcet in the rest of the world.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Financing
Royalty Sale
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?